St. Gallen 2011: Summary of the Consensus Discussion

被引：176

作者：

Gnant, Michael ^{[1
]}

Harbeck, Nadia ^{[2
]}

Thomssen, Christoph ^{[3
]}

机构：

[1] Med Univ Wien, Univ Klin Chirurg, Comprehens Canc Ctr MUW AKH, A-1090 Vienna, Austria

[2] Univ Klinikum Koln, Klin & Poliklin Frauenheilkunde & Geburtshilfe, Brustzentrum, Cologne, Germany

[3] Univ Halle Wittenberg, Klin & Poliklin Gynakol, Halle, Germany

来源：

BREAST CARE | 2011年 / 6卷 / 02期

关键词：

Early breast cancer; Bisphosphonates; Endocrine therapy; Chemotherapy; Surgery; Targeted therapy; Neoadjuvant therapy; BREAST-CANCER PATIENTS; ACTIVATOR INHIBITOR TYPE-1; ADJUVANT CHEMOTHERAPY; PLASMINOGEN-ACTIVATOR; HIGH-RISK; THERAPY; TRIAL; WOMEN; UPA;

D O I：

10.1159/000328054

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The 2011 St. Gallen Consensus Conference on early breast cancer provided mostly evidence-based treatment recommendations with a broad spectrum of acceptable clinical practice for global breast cancer care. This report summarizes the results of the 2011 international panel voting procedures with regard to locoregional and endocrine treatment, chemotherapy, targeted therapy as well as adjuvant bisphosphonate use.

引用

页码：136 / 141

页数：6

共 15 条

[1]

COLEMAN R, 2010, CANC RES S, V70

[2] Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study [J].

Eidtmann, H. ;

de Boer, R. ;

Bundred, N. ;

Llombart-Cussac, A. ;

Davidson, N. ;

Neven, P. ;

von Minckwitz, G. ;

Miller, J. ;

Schenk, N. ;

Coleman, R. .

ANNALS OF ONCOLOGY, 2010, 21 (11) :2188-2194

[3]

Gianni L, 2010, NEOADJUVANT PERTUZUM, pS3

[4] Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis A Randomized Clinical Trial [J].

Giuliano, Armando E. ;

Hunt, Kelly K. ;

Ballman, Karla V. ;

Beitsch, Peter D. ;

Whitworth, Pat W. ;

Blumencranz, Peter W. ;

Leitch, A. Marilyn ;

Saha, Sukamal ;

McCall, Linda M. ;

Morrow, Monica .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (06) :569-575

[5]

GNANT M, N ENGL J MED, V360, P679

[6] First-select the target:: better choice of adjuvant treatments for breast cancer patients [J].

Goldhirsch, A. ;

Coates, A. S. ;

Gelber, R. D. ;

Glick, J. H. ;

Thuerlimann, B. ;

Senn, H. -J. .

ANNALS OF ONCOLOGY, 2006, 17 (12) :1772-1776

[7] Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 [J].

Goldhirsch, A. ;

Ingle, J. N. ;

Gelber, R. D. ;

Coates, A. S. ;

Thuerlimann, B. ;

Senn, H. -J. .

ANNALS OF ONCOLOGY, 2009, 20 (08) :1319-1329

[8]

Harbeck N, 2002, CANCER RES, V62, P4617

[9] A New Look at Node-Negative Breast Cancer [J].

Harbeck, Nadia ;

Thomssen, Christoph .

ONCOLOGIST, 2011, 16 :51-60

[10] Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 [J].

Jänicke, F ;

Prechtl, A ;

Thomssen, C ;

Harbeck, N ;

Meisner, C ;

Untch, M ;

Sweep, CGJF ;

Selbmann, HK ;

Graeff, H ;

Schmitt, M .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (12) :913-920

← 1 2 →